Skip to content
2000
Volume 9, Issue 9
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

There is a rapid expansion in the number of new anti-cancer drugs with remarkably different mechanisms of action that can augment traditional chemotherapy. As these agents are often used in combination with traditional chemotherapy testing the effects of these novel agents has proven difficult requiring large sample sizes to detect relatively small differences in patient survival. Despite the wide variety of mechanisms, most new drugs are thought to ultimately induce apoptosis of tumor cells or their supportive vasculature. Imaging agents that can non-invasively monitor apoptosis in response to these new drugs could therefore help streamline the drug development process. They may also help guide oncologists to identify those patients that could best benefit from a given therapeutic regimen, dose, or duration of drug. In this article we will outline the existing imaging agents and modalities that are currently undergoing clinical testing and those that could be rapidly translated into humans.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/187152009789377727
2009-11-01
2025-09-16
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/187152009789377727
Loading

  • Article Type:
    Research Article
Keyword(s): Apoptosis; MRI; oncology; PET; SPECT
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test